ArticleScience advances2025
Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD
Abstract read
In one paragraph
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men.Scientific reports · 2026Trial
- The differential impact of three different NADNature metabolism · 2026Trial
- The Gut Microbiota-Metabolite-Host Axis in Cardiometabolic Diseases: Bridging Bench to Bedside.Cardiovascular drugs and therapy · 2026Review
- Article
- NAMPT activation uncovers a senescence-specific vulnerability and promotes healthy aging in combination with NAM.bioRxiv : the preprint server for biology · 2026Article
- Exogenous Nucleotides as Functional Food Supplements: A Bibliometric Analysis of Global Research Trends (2000-2025).Foods (Basel, Switzerland) · 2026Review
- Double-Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration.Aging cell · 2026 · on this mapArticle
- Epidermal NAD+ deficiency induces IL-36-mediated skin inflammation and acanthosis.JCI insight · 2026Article
- The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation.iScience · 2026Article
- Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights.Nutrients · 2026Review
- Effects of nicotinamide riboside supplementation during late gestation and lactation on sow performance, milk metabolome, and gut microbiome.Journal of animal science and biotechnology · 2026Article
- Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Mitochondrial control of blood-brain barrier homeostasis in neuroinflammatory psychiatric disorders.Frontiers in molecular neuroscience · 2026Review
- Nicotinamide mononucleotide alleviates the streptozotocin-mediated ferroptosis of islet β-cells via the Nrf2/GPX4 pathway.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- The microbiome at the centre of NADNature metabolism · 2026Article
- From Bench to Clinic: The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling.Molecular medicine (Cambridge, Mass.) · 2025Article
- The Role of Hepatic SIRT1: From Metabolic Regulation to Immune Modulation and Multi-target Therapeutic Strategies.Journal of clinical and translational hepatology · 2025Review
- Effects of Nicotinamide Mononucleotide Supplementation and Aerobic Exercise on Metabolic Health and Physical Performance in Aged Mice.Nutrients · 2025Article
- NADNature metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Keisuke YakuDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-2420-4265
Sailesh PalikheDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0003-2511-9043
Tooba IqbalDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0009-0002-8207-3678
Faisal HayatMitchell Cancer Institute, Department of Pharmacology, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36693, USA.ORCID 0000-0001-5493-0199
Yoshiyuki WatanabeFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0009-0000-6921-8188
Shiho FujisakaFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0003-0554-9003
Hironori IzumiDepartment of Molecular Neuroscience, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0009-0007-7580-1987
Tomoyuki YoshidaDepartment of Molecular Neuroscience, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-8476-3798
Mariam KarimDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0009-0005-1770-6477
Hitoshi UchidaDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-5372-5134
Allah NawazDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-1979-9575
Kazuyuki TobeFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0003-0015-0255
Hisashi MoriDepartment of Molecular Neuroscience, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-9743-2456
Marie E MigaudMitchell Cancer Institute, Department of Pharmacology, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36693, USA.ORCID 0000-0002-9626-2405
Takashi NakagawaDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-5539-7605
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decreased nicotinamide adenine dinucleotide (oxidized form) (NAD
Indexed as
NADNiacinamideNicotinamide MononucleotidePyridinium CompoundsAdministration, OralAnimalsGastrointestinal MicrobiomeLiverMaleMetabolomicsMiceMice, Inbred C57BLNADNiacinamidenicotinamide-beta-ribosideNicotinamide MononucleotidePyridinium Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.